Rheumatologic Disorders and Their Ocular Manifestations – Clinical Insights and Therapeutic Approaches
DOI:
https://doi.org/10.12775/JEHS.2025.78.57592Keywords
Uveitis in rheumatic diseases, Spondyloarthropathies, Systemic lupus erythematosus, HLA B27 uveitis, Treatment of rheumatic diseasesAbstract
Introduction and purpose: Rheumatic disorders, a broad group of conditions primarily affecting the joints, can have significant systemic manifestations that extend beyond musculoskeletal involvement. One such often-overlooked aspect of these diseases is the impact they can have on the eyes. Ocular symptoms are common in many rheumatic diseases and can range from mild irritation to severe sight-threatening complications. This article explores the range of ocular symptoms associated with rheumatic diseases, emphasizing their clinical presentations and the importance of early recognition and treatment.
Materials and methods: A review was conducted in PubMed including publications regarding ocular manifestations of rheumatic diseases. Literature was searched using the following terms: “uveitis in rheumatic disorders”, “spondyloarthropathies”, “systemic lupus erythematosus”, “HLA B27 uveitis” and “treatment of rheumatic diseases”.
Brief description of the state of knowledge: The eyes may be affected either directly through inflammation of various ocular structures or indirectly as part of the systemic manifestations of autoimmune processes. Conditions such as rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome and ankylosing spondylitis often present with ocular involvement including dry eye syndrome, uveitis, scleritis, episcleritis and retinal vasculitis. While some ocular findings may be asymptomatic others can lead to significant visual impairment if not properly managed.
Conclusions: Rheumatic diseases are often associated with a range of ophthalmic complications which can sometimes develop before any other systemic signs of the rheumatic condition appear, making them crucial indicators of potential underlying disease. In many cases, the visual system may be the first to show signs of involvement and recognizing these symptoms early is essential for timely diagnosis and management.
References
1. Szaflik J, Bachta A, Kulig M, Tłustochowicz M, Stankiewicz A, Tłustochowicz W. Leczenie farmakologiczne chorych na nawrotowe idiopatyczne zapalenie przedniego odcinka błony naczyniowej oka [Pharmacological treatment of recurrent idiopathic anterior uveitis]. Klin Oczna. 2011;113(4-6):111-6. Polish. PMID: 21913437.
2. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008 Jul;67(7):955-9. doi: 10.1136/ard.2007.075754. Epub 2007 Oct 25. PMID: 17962239.
3. Muñoz-Fernández S, Martín-Mola E. Uveitis. Best Pract Res Clin Rheumatol. 2006 Jun;20(3):487-505. doi: 10.1016/j.berh.2006.03.008. PMID: 16777578.
4. Bhamra MS, Gondal I, Amarnani A, et al. Ocular Manifestations of Rheumatoid Arthritis: Implications of Recent Clinical Trials. Int J Clin Res Trials 2019;4:139. https://doi.org/10.15344/2456-8007/2019/139
5. Marcinów-Ostapczuk M. Scleritis and Episcleritis – Modern Diagnostic and Treatment Options. Ophthalmological Review 2012;48(4):1-2
6. Rademacher J, Poddubnyy D, Pleyer U. Uveitis in spondyloarthritis. Ther Adv Musculoskelet Dis. 2020 Sep 12;12:1759720X20951733. doi: 10.1177/1759720X20951733. PMID: 32963592; PMCID: PMC7488890.
7. Felis-Giemza A. Spondyloarthropathy and Organ Changes — A Comprehensive Approach to the Patient. Forum Reumatol 2017;3(3):160-7, https://journals.viamedica.pl/varia_medica/article/view/55751
8. Ebrahimiadib N, Berijani S, Ghahari M, Pahlaviani FG. Ankylosing Spondylitis. J Ophthalmic Vis Res. 2021 Jul 29;16(3):462-469. doi: 10.18502/jovr.v16i3.9440. PMID: 34394873; PMCID: PMC8358754.
9. Cantini F, Nannini C, Cassarà E, Kaloudi O, Niccoli L. Uveitis in Spondyloarthritis: An Overview. J Rheumatol Suppl. 2015 Nov;93:27-9. doi: 10.3899/jrheum.150630. PMID: 26523051.
10. Sun L, Wu R, Xue Q, Wang F, Lu P. Risk factors of uveitis in ankylosing spondylitis: An observational study. Medicine (Baltimore). 2016 Jul;95(28):e4233. doi: 10.1097/MD.0000000000004233. PMID: 27428230; PMCID: PMC4956824.
11. Kwiatkowska B, Maslinsk M. Ocular Symptoms (Conjunctivitis, Uveitis) in Reactive Arthritis [Internet]. Conjunctivitis - A Complex and Multifaceted Disorder. InTech; 2011. Available from: http://dx.doi.org/10.5772/26431
12. Carlin E, Flew S. Sexually acquired reactive arthritis. Clin Med (Lond). 2016 Apr;16(2):193-6. doi: 10.7861/clinmedicine.16-2-193. PMID: 27037393; PMCID: PMC4952977.
13. Kemeny-Beke A, Szodoray P. Ocular manifestations of rheumatic diseases. Int Ophthalmol. 2020 Feb;40(2):503-510. doi: 10.1007/s10792-019-01183-9. Epub 2019 Oct 3. PMID: 31583550.
14. Mady R, Grover W, Butrus S. Ocular complications of inflammatory bowel disease. ScientificWorldJournal. 2015;2015:438402. doi: 10.1155/2015/438402. Epub 2015 Mar 23. PMID: 25879056; PMCID: PMC4386693.
15. Canouï-Poitrine F, Lekpa FK, Farrenq V, Boissinot V, Hacquard-Bouder C, Comet D, Bastuji-Garin S, Thibout E, Claudepierre P. Prevalence and factors associated with uveitis in spondylarthritis patients in France: results from an observational survey. Arthritis Care Res (Hoboken). 2012 Jun;64(6):919-24. doi: 10.1002/acr.21616. Epub 2012 Jan 19. PMID: 22262475.
16. Juanola X, Loza Santamaría E, Cordero-Coma M; SENTINEL Working Group. Description and Prevalence of Spondyloarthritis in Patients with Anterior Uveitis: The SENTINEL Interdisciplinary Collaborative Project. Ophthalmology. 2016 Aug;123(8):1632-1636. doi: 10.1016/j.ophtha.2016.03.010. Epub 2016 Apr 12. PMID: 27084561.
17. Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, Colbert RA, Feldman BM, Ferguson PJ, Gewanter H, Guzman J, Horonjeff J, Nigrovic PA, Ombrello MJ, Passo MH, Stoll ML, Rabinovich CE, Schneider R, Halyabar O, Hays K, Shah AA, Sullivan N, Szymanski AM, Turgunbaev M, Turner A, Reston J. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Rheumatol. 2019 Jun;71(6):846-863. doi: 10.1002/art.40884. Epub 2019 Apr 25. PMID: 31021537; PMCID: PMC6561114.
18. Clarke SL, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol Online J. 2016 Apr 27;14(1):27. doi: 10.1186/s12969-016-0088-2. PMID: 27121190; PMCID: PMC4848803.
19. Rypdal V, Glerup M, Songstad NT, Bertelsen G, Christoffersen T, Arnstad ED, Aalto K, Berntson L, Fasth A, Herlin T, Ekelund M, Peltoniemi S, Toftedal P, Nielsen S, Leinonen S, Bangsgaard R, Nielsen R, Rygg M, Nordal E; Nordic Study Group of Pediatric Rheumatology. Uveitis in Juvenile Idiopathic Arthritis: 18-Year Outcome in the Population-based Nordic Cohort Study. Ophthalmology. 2021 Apr;128(4):598-608. doi: 10.1016/j.ophtha.2020.08.024. Epub 2020 Aug 29. PMID: 32866542.
20. Rutkowska-Sak L, Gietka P. Uveitis associated juvenile idiopathic arthritis - presentation of recently published international recommendations for diagnostic and therapeutic procedures. Reumatologia. 2020;58(5):277-281. doi: 10.5114/reum.2020.100169. Epub 2020 Oct 29. PMID: 33227093; PMCID: PMC7667942.
21. Garner AJ, Saatchi R, Ward O, Hawley DP. Juvenile Idiopathic Arthritis: A Review of Novel Diagnostic and Monitoring Technologies. Healthcare (Basel). 2021 Dec 4;9(12):1683. doi: 10.3390/healthcare9121683. PMID: 34946409; PMCID: PMC8700900.
22. Carlsson E, Beresford MW, Ramanan AV, Dick AD, Hedrich CM. Juvenile Idiopathic Arthritis Associated Uveitis. Children (Basel). 2021 Jul 27;8(8):646. doi: 10.3390/children8080646. PMID: 34438537; PMCID: PMC8393258.
23. Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K; German Uveitis in Childhood Study Group. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford). 2007 Jun;46(6):1015-9. doi: 10.1093/rheumatology/kem053. Epub 2007 Apr 2. PMID: 17403710.
24. Constantin T, Foeldvari I, Anton J, de Boer J, Czitrom-Guillaume S, Edelsten C, Gepstein R, Heiligenhaus A, Pilkington CA, Simonini G, Uziel Y, Vastert SJ, Wulffraat NM, Haasnoot AM, Walscheid K, Pálinkás A, Pattani R, Györgyi Z, Kozma R, Boom V, Ponyi A, Ravelli A, Ramanan AV. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018 Aug;77(8):1107-1117. doi: 10.1136/annrheumdis-2018-213131. Epub 2018 Mar 28. PMID: 29592918; PMCID: PMC6059050.
25. Palejwala NV, Walia HS, Yeh S. Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmune Dis. 2012;2012:290898. doi: 10.1155/2012/290898. Epub 2012 Jul 2. PMID: 22811887; PMCID: PMC3395333.
26. Silpa-archa S, Lee JJ, Foster CS. Ocular manifestations in systemic lupus erythematosus. Br J Ophthalmol. 2016 Jan;100(1):135-41. doi: 10.1136/bjophthalmol-2015-306629. Epub 2015 Apr 22. PMID: 25904124.
27. Szucs G, Szekanecz Z, Aszalos Z, Gesztelyi R, Zsuga J, Szodoray P, Kemeny-Beke A. A Wide Spectrum of Ocular Manifestations Signify Patients with Systemic Sclerosis. Ocul Immunol Inflamm. 2021 Jan 2;29(1):81-89. doi: 10.1080/09273948.2019.1657467. Epub 2019 Oct 2. PMID: 31577461.
28. Choudhary MM, Hajj-Ali RA, Lowder CY. Gender and ocular manifestations of connective tissue diseases and systemic vasculitides. J Ophthalmol. 2014;2014:403042. doi: 10.1155/2014/403042. Epub 2014 Mar 17. PMID: 24757559; PMCID: PMC3976932.
29. Kozikowska M, Luboń W, Kucharz EJ, Mrukwa-Kominek E. Ocular manifestations in patients with systemic sclerosis. Reumatologia. 2020;58(6):401-406. doi: 10.5114/reum.2020.102004. Epub 2020 Dec 23. PMID: 33456083; PMCID: PMC7792544.
30. Maślińska M. Introductory Chapter: Autoimmune Epithelitis - Discussion about Sjögren’s Syndrome and Primary Biliary Cholangitis [Internet]. Chronic Autoimmune Epithelitis - Sjogren’s Syndrome and Other Autoimmune Diseases of the Exocrine Glands. IntechOpen; 2019. Available from: http://dx.doi.org/10.5772/intechopen.86258
31. Roszkowska AM, Oliverio GW, Aragona E, Inferrera L, Severo AA, Alessandrello F, Spinella R, Postorino EI, Aragona P. Ophthalmologic Manifestations of Primary Sjögren's Syndrome. Genes (Basel). 2021 Mar 4;12(3):365. doi: 10.3390/genes12030365. PMID: 33806489; PMCID: PMC7998625.
32. Titsinides S, Nikitakis N, Piperi E, Sklavounou A. MALT Lymphoma of Minor Salivary Glands in a Sjögren's Syndrome Patient: a Case Report and Review of Literature. J Oral Maxillofac Res. 2017 Mar 31;8(1):e5. doi: 10.5037/jomr.2017.8105. PMID: 28496965; PMCID: PMC5423310.
33. Kopacz D, Maciejewicz P. Sjögren’s Syndrome as an Ocular Problem: Signs and Symptoms, Diagnosis, Treatment [Internet]. Chronic Autoimmune Epithelitis - Sjogren’s Syndrome and Other Autoimmune Diseases of the Exocrine Glands. IntechOpen; 2019. Available from: http://dx.doi.org/10.5772/intechopen.83821
34. Mathews PM, Robinson SA, Gire A, Baer AN, Akpek EK. Extraglandular ocular involvement and morbidity and mortality in primary Sjögren's Syndrome. PLoS One. 2020 Sep 25;15(9):e0239769. doi: 10.1371/journal.pone.0239769. PMID: 32976549; PMCID: PMC7518584.
35. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, Mariette X; International Sjögren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol. 2017 Jan;69(1):35-45. doi: 10.1002/art.39859. Epub 2016 Oct 26. PMID: 27785888; PMCID: PMC5650478.
36. Uribe-Reina P, Muñoz-Ortiz J, Cifuentes-González C, Reyes-Guanes J, Terreros-Dorado JP, Zambrano-Romero W, López-Rojas C, Mantilla-Sylvain F, Mantilla-Hernández RD, de-la-Torre A. Ocular Manifestations in Colombian Patients with Systemic Rheumatologic Diseases. Clin Ophthalmol. 2021 Jun 28;15:2787-2802. doi: 10.2147/OPTH.S306621. PMID: 34234401; PMCID: PMC8254180.
37. Ruiz-Lozano RE, Velazquez-Valenzuela F, Roman-Zamudio M, Andrade-Leal SK, Rodriguez-Garcia A. Polymyositis and dermatomyositis: ocular manifestations and potential sight-threatening complications. Rheumatol Int. 2022 Jul;42(7):1119-1131. doi: 10.1007/s00296-021-05035-7. Epub 2021 Oct 21. PMID: 34674015.
38. Foroozan R. Visual loss from optic neuropathy in dermatomyositis. Rheumatology (Oxford). 2004 Mar;43(3):391-3. doi: 10.1093/rheumatology/keh040. PMID: 14963209.
39. Fukuda K, Mizobuchi T, Nakajima I, Kishimoto T, Miura Y, Taniguchi Y. Ocular Involvement in Relapsing Polychondritis. J Clin Med. 2021 Oct 26;10(21):4970. doi: 10.3390/jcm10214970. PMID: 34768492; PMCID: PMC8584789.
40. Maritati F, Peyronel F, Vaglio A. IgG4-related disease: a clinical perspective. Rheumatology (Oxford). 2020 May 1;59(Suppl 3):iii123-iii131. doi: 10.1093/rheumatology/kez667. PMID: 32348524.
41. Yu WK, Tsai CC, Kao SC, Liu CJ. Immunoglobulin G4-related ophthalmic disease. Taiwan J Ophthalmol. 2018 Jan-Mar;8(1):9-14. doi: 10.4103/tjo.tjo_12_17. PMID: 29675343; PMCID: PMC5890589.
42. Goto H, Ueda SI, Nemoto R, Ohshima KI, Sogabe Y, Kitagawa K, Ogawa Y, Oyama T, Furuta M, Azumi A, Takahira M. Clinical features and symptoms of IgG4-related ophthalmic disease: a multicenter study. Jpn J Ophthalmol. 2021 Sep;65(5):651-656. doi: 10.1007/s10384-021-00847-3. Epub 2021 Jun 19. PMID: 34146222.
43. Chen TS, Figueira E, Lau OC, McKelvie PA, Smee RI, Dawes LC, Agar A, Wilcsek G, Francis IC. Successful "medical" orbital decompression with adjunctive rituximab for severe visual loss in IgG4-related orbital inflammatory disease with orbital myositis. Ophthalmic Plast Reconstr Surg. 2014 Sep-Oct;30(5):e122-5. doi: 10.1097/IOP.0b013e3182a64fa4. PMID: 24481505.
44. Zhang W, Luo J, Jiao J. Optic nerve involvement in immunoglobulin G4-related disease: A case report. Exp Ther Med. 2016 Jul;12(1):111-114. doi: 10.3892/etm.2016.3291. Epub 2016 Apr 26. PMID: 27347025; PMCID: PMC4906810.
45. Ohshima K, Sogabe Y, Sato Y. The usefulness of infraorbital nerve enlargement on MRI imaging in clinical diagnosis of IgG4-related orbital disease. Jpn J Ophthalmol. 2012 Jul;56(4):380-2. doi: 10.1007/s10384-012-0151-6. Epub 2012 May 30. PMID: 22644450.
46. Derzko-Dzulynsky L. IgG4-related disease in the eye and ocular adnexa. Curr Opin Ophthalmol. 2017 Nov;28(6):617-622. doi: 10.1097/ICU.0000000000000427. PMID: 28858963.
47. Wu A, Andrew NH, McNab AA, Selva D. Bilateral IgG4-related ophthalmic disease: a strong indication for systemic imaging. Br J Ophthalmol. 2016 Oct;100(10):1409-11. doi: 10.1136/bjophthalmol-2015-307437. Epub 2015 Dec 30. PMID: 26719494.
48. Chougule A, Bal A, Das A, Agarwal R, Singh N, Rao KL. A Comparative Study of Inflammatory Myofibroblastic Tumors and Tumefactive IgG4-related Inflammatory Lesions: the Relevance of IgG4 Plasma Cells. Appl Immunohistochem Mol Morphol. 2016 Nov/Dec;24(10):721-728. doi: 10.1097/PAI.0000000000000252. PMID: 26469330.
49. Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire JF, Hart PA, Inoue D, Kawano M, Khosroshahi A, Kubota K, Lanzillotta M, Okazaki K, Perugino CA, Sharma A, Saeki T, Sekiguchi H, Schleinitz N, Stone JR, Takahashi N, Umehara H, Webster G, Zen Y, Stone JH; American College of Rheumatology/European League Against Rheumatism IgG4-Related Disease Classification Criteria Working Group. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. Arthritis Rheumatol. 2020 Jan;72(1):7-19. doi: 10.1002/art.41120. Epub 2019 Dec 2. PMID: 31793250.
50. Sfiniadaki E, Tsiara I, Theodossiadis P, Chatziralli I. Ocular Manifestations of Granulomatosis with Polyangiitis: A Review of the Literature. Ophthalmol Ther. 2019 Jun;8(2):227-234. doi: 10.1007/s40123-019-0176-8. Epub 2019 Mar 15. PMID: 30875067; PMCID: PMC6513923.
51. Orazbekov L, Issergepova B, Assainova M, Ruslanuly K. Granulomatosis with Polyangiitis with Ocular Manifestations. Case Rep Ophthalmol. 2021 Apr 6;12(1):98-104. doi: 10.1159/000510959. PMID: 33976664; PMCID: PMC8077634.
52. Pérez-Jacoiste Asín MA, Charles P, Rothschild PR, Terrier B, Brézin A, Mouthon L, Guillevin L, Puéchal X. Ocular involvement in granulomatosis with polyangiitis: A single-center cohort study on 63 patients. Autoimmun Rev. 2019 May;18(5):493-500. doi: 10.1016/j.autrev.2019.03.001. Epub 2019 Mar 4. PMID: 30844550.
53. Akella SS, Schlachter DM, Black EH, Barmettler A. Ophthalmic Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome): A Systematic Review of the Literature. Ophthalmic Plast Reconstr Surg. 2019 Jan/Feb;35(1):7-16. doi: 10.1097/IOP.0000000000001202. PMID: 30134390.
54. Zając H, Turno-Kręcicka A. Ocular Manifestations of Behçet's Disease: An Update on Diagnostic Challenges and Disease Management. J Clin Med. 2021 Nov 5;10(21):5174. doi: 10.3390/jcm10215174. PMID: 34768694; PMCID: PMC8584626.
55. Çakar Özdal P. Behçet's Uveitis: Current Diagnostic and Therapeutic Approach. Turk J Ophthalmol. 2020 Jun 27;50(3):169-182. doi: 10.4274/tjo.galenos.2019.60308. PMID: 32631005; PMCID: PMC7338748.
56. Posarelli C, Maglionico MN, Talarico R, Covello G, Figus M. Behçet's syndrome and ocular involvement: changes over time. Clin Exp Rheumatol. 2020 Sep-Oct;38 Suppl 127(5):86-93. Epub 2020 Nov 18. PMID: 33253088.
57. Turk MA, Hayworth JL, Nevskaya T, Pope JE. Ocular Manifestations in Rheumatoid Arthritis, Connective Tissue Disease, and Vasculitis: A Systematic Review and Metaanalysis. J Rheumatol. 2021 Jan 1;48(1):25-34. doi: 10.3899/jrheum.190768. Epub 2020 May 1. PMID: 32358156.
58. Burkholder BM, Jabs DA. Uveitis for the non-ophthalmologist. BMJ. 2021 Feb 3;372:m4979. doi: 10.1136/bmj.m4979. PMID: 33536186.
59. Pasadhika S, Rosenbaum JT. Ocular Sarcoidosis. Clin Chest Med. 2015 Dec;36(4):669-83. doi: 10.1016/j.ccm.2015.08.009. PMID: 26593141; PMCID: PMC4662043.
60. Kwiatkowska E, Turno-Kręcicka A, Berus T. Tubulointerstitial nephritis and uveitis – case report. Klinika Oczna / Acta Ophthalmologica Polonica. 2016;118(2):147-150. doi:10.5114/ko.2016.71692.
61. Thorne JE, Woreta F, Kedhar SR, Dunn JP, Jabs DA. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol. 2007 May;143(5):840-846. doi: 10.1016/j.ajo.2007.01.033. Epub 2007 Mar 23. PMID: 17362866.
62. Gregory AC 2nd, Kempen JH, Daniel E, Kaçmaz RO, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Research Group. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology. 2013 Jan;120(1):186-92. doi: 10.1016/j.ophtha.2012.07.052. Epub 2012 Oct 11. PMID: 23062650; PMCID: PMC3536914.
63. Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010 Jul;117(7):1436-41. doi: 10.1016/j.ophtha.2009.12.003. Epub 2010 Apr 3. PMID: 20363502; PMCID: PMC2900491.
64. Stroh IG, Moradi A, Burkholder BM, Hornbeak DM, Leung TG, Thorne JE. Occurrence of and Risk Factors for Ocular Hypertension and Secondary Glaucoma in Juvenile Idiopathic Arthritis-associated Uveitis. Ocul Immunol Inflamm. 2017 Aug;25(4):503-512. doi: 10.3109/09273948.2016.1142573. Epub 2016 Mar 22. PMID: 27003850.
65. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011 Jan 5;52(1):80-6. doi: 10.1167/iovs.10-5285. PMID: 20702826.
66. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007 Mar;125(3):309-17. doi: 10.1001/archopht.125.3.309. PMID: 17353400.
67. Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM; Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011 May;129(5):545-53. doi: 10.1001/archophthalmol.2010.339. Epub 2011 Jan 10. PMID: 21220619.
68. Thorne JE, Sugar EA, Holbrook JT, Burke AE, Altaweel MM, Vitale AT, Acharya NR, Kempen JH, Jabs DA; Multicenter Uveitis Steroid Treatment Trial Research Group. Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology. 2019 Feb;126(2):283-295. doi: 10.1016/j.ophtha.2018.08.021. Epub 2018 Sep 27. PMID: 30269924; PMCID: PMC6348060.
69. Jabs DA. Treatment of ocular inflammation. Ocul Immunol Inflamm. 2004 Sep;12(3):163-8. doi: 10.1080/09273940490883671. PMID: 15385193.
70. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000 Oct;130(4):492-513. doi: 10.1016/s0002-9394(00)00659-0. PMID: 11024423.
71. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Inês LB, de Koning EJ, Buttgereit F, Cutolo M, Capell H, Rau R, Bijlsma JW. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006 Mar;65(3):285-93. doi: 10.1136/ard.2005.038638. Epub 2005 Aug 17. PMID: 16107513; PMCID: PMC1798053.
72. Hwang YG, Saag K. The safety of low-dose glucocorticoids in rheumatic diseases. Clin Exp Rheumatol. 2011 Sep-Oct;29(5 Suppl 68):S104-12. Epub 2011 Oct 22. PMID: 22018194.
73. Charkoudian LD, Ying GS, Pujari SS, Gangaputra S, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Kempen JH. High-dose intravenous corticosteroids for ocular inflammatory diseases. Ocul Immunol Inflamm. 2012 Apr;20(2):91-9. doi: 10.3109/09273948.2011.646382. PMID: 22409561; PMCID: PMC3306126.
74. Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992 Feb 27;326(9):581-8. doi: 10.1056/NEJM199202273260901. PMID: 1734247.
75. Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001 Jun;108(6):1134-9. doi: 10.1016/s0161-6420(01)00576-0. PMID: 11382642.
76. Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Bañares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond). 2000 Jun;14 ( Pt 3A):340-3. doi: 10.1038/eye.2000.84. PMID: 11026996.
77. Figueroa MS, Ciancas E, Orte L. Long-term follow-up of tacrolimus treatment in immune posterior uveitis. Eur J Ophthalmol. 2007 Jan-Feb;17(1):69-74. doi: 10.1177/112067210701700110. PMID: 17294385.
78. Amador-Patarroyo MJ, Cristina Peñaranda A, Teresa Bernal M. Autoimmune uveitis. In: Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al., editors. Autoimmunity: From Bench to Bedside [Internet]. Bogota (Colombia): El Rosario University Press; 2013 Jul 18. Chapter 37. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459445/
79. Takeuchi M. A systematic review of biologics for the treatment of noninfectious uveitis. Immunotherapy. 2013 Jan;5(1):91-102. doi: 10.2217/imt.12.134. PMID: 23256801.
80. Tugal-Tutkun I. Behçet's Uveitis. Middle East Afr J Ophthalmol. 2009 Oct;16(4):219-24. doi: 10.4103/0974-9233.58425. PMID: 20404988; PMCID: PMC2855662.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Agnieszka Borowiec, Kinga Borowiec

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 64
Number of citations: 0